Don P Cameron 25th Lorne Cancer Conference 2013

Abstracts this author is presenting:

• Designing molecular biomarkers of therapeutic response to CX-5461, a first-in-class RNA Polymerase I inhibitor, for an upcoming Phase I clinical trial — Poster Session 1